CommercialCoverageMedium impact
Tuberculosis Testing (CPB 0471, reviewed 2026-07-23)
Aetna·Infectious Disease, Internal Medicine, Pediatrics +4 more·Medical Policy
Effective date
Jul 23, 2026
We identified it
Aug 12, 2026
Summary
Aetna has updated its tuberculosis testing policy (CPB 0471, effective 2026-07-23) to clarify coverage for multiple testing methodologies including Mantoux skin test, QuantiFERON tests, rapid molecular testing for drug-resistant TB, and urine-based lipoarabinomannan antigen testing for HIV+ patients. The policy explicitly excludes coverage for experimental tests including AI screening, biomarker-based non-sputum tests, breath tests, CRISPR-TB blood tests, and whole genome sequencing. Billing teams must ensure claims are submitted with correct CPT codes and that claims for excluded experimental tests are rejected or not submitted.
Action Required
By 2026-07-23: Billing team must update billing system to reflect Aetna coverage for covered TB tests (CPT 86480, 86481, 86580, 87556, 87564, 87798, and others listed) and implement hard-stop denials or rejection rules for non-covered experimental codes including 0574U, 0629U, 81425, 81426, 81427 (whole genome sequencing), and any claims with modifiers indicating AI screening, biomarker non-sputum tests, breath tests, or molecular stool tests. Verify that claims for TNF-alpha inhibitor patients (J0139, J1438, J1745, Q5103-Q5145) include documentation of TB screening prior to treatment initiation per policy selection criteria. Training required for billing staff on medical necessity criteria for TB screening—ensure providers document patient meets one of the listed high-risk categories or medical conditions before submitting claims. Flag any claims for excluded tests to providers for education. Update claim denial messages to reference specific exclusions per this policy bulletin.